Brief: Oncolytics Biotech enters collaboration with Myeloma UK and Celgene
March 16 (Reuters) - Oncolytics Biotech Inc ONC.TO
* Oncolytics biotech enters into first-in-class
collaboration with Myeloma UK and Celgene using Reolysin in
combination with Imnovid or Revlimid in patients with Myeloma
* Phase 1b trial will study immuno-viral therapy, Reolysin
in combination with Celgene Corporation's immunomodulatory drugs
Source text for Eikon: ID:nPn7hyg68a
Further company coverage: ONC.TO
(Bangalore.newsroom@thomsonreuters.com)
Recent news on Oncolytics Biotech
See all newsBrief: Oncolytics Biotech Announces Clinical Supply Agreement To Evaluate Pelareorep In Combination With Loqtorzi In Squamous Cell Anal Carcinoma
Brief: Oncolytics Says Pelareorep Shows Durable Survival Benefit in Anal Cancer
Brief: Oncolytics Biotech Expects Final Cohort 4 Results Of Goblet Study In Q4 2026
Brief: Oncolytics Biotech® Secures Patent Protection To Late 2040S And Provides Intellectual Property Portfolio Update
Brief: Oncolytics Biotech® Aligns With FDA On Registrational Path For Second-Line Ras-Mutant Mss Colorectal Cancer